8 results on '"Nebulization"'
Search Results
2. Nebulized lignocaine for topical anaesthesia in no-sedation bronchoscopy (NEBULA): A randomized, double blind, placebo-controlled trial
- Author
-
Karan Madan, Shiba Kalyan Biswal, Pawan Tiwari, Saurabh Mittal, Vijay Hadda, Anant Mohan, Gopi C Khilnani, and Randeep Guleria
- Subjects
Bronchoscopy ,cough ,lignocaine ,nebulization ,Diseases of the respiratory system ,RC705-779 - Abstract
Background: The role of nebulized lignocaine administration for flexible bronchoscopy is unclear. Methods: In this randomized, double-blind, placebo-controlled trial, subjects undergoing diagnostic flexible bronchoscopy were randomized to receive either nebulized lignocaine (2.5 ml of 4% lignocaine) or nebulized (2.5 ml of 0.9%) saline (placebo). All received 10% lignocaine pharyngeal spray (4 sprays) and 5-ml nasal 2% lignocaine gel. 1% lignocaine solution was used for spray-as-you-go administration in all. Co-primary outcomes were Operator-rated overall procedure satisfaction and Operator-rated cough scores on Visual Analog Scale (VAS). Secondary objectives were cumulative lignocaine dose, proportion of subjects receiving >8.2-mg/kg lignocaine, and complications between the groups. Results: Two hundred and twenty subjects were randomized and 217 (109 – nebulized lignocaine and 108 – placebo) received the intervention. Baseline characteristics were comparable. Operator-rated overall procedure satisfaction scores on VAS (7.30 ± 1.54 nebulized lignocaine and 7.50 ± 1.31 placebo group,P = 0.85) and Operator-rated cough scores on VAS (3 [2–5] nebulized lignocaine and 3 [2–4] placebo group,P = 0.18) were similar. Cumulative lignocaine dose was significantly greater in nebulized lignocaine group (331.46 ± 9.41 mg vs. 232.22 ± 12.77 mg,P < 0.001), and a significantly greater number of subjects in this group received lignocaine dose >8.2 mg/kg. Minor complications occurred in 6 and 9 subjects in nebulized lignocaine and placebo groups, respectively,P = 0.41. Conclusion: Administration of nebulized lignocaine in addition to pharyngeal lignocaine spray, during no-sedation bronchoscopy, increases the cumulative lignocaine dose without improved procedural comfort. Additional nebulized lignocaine during bronchoscopy is not recommended.
- Published
- 2019
- Full Text
- View/download PDF
3. The emerging role of nebulization for maintenance treatment of chronic obstructive pulmonary disease at home.
- Author
-
Talwar, Deepak, Ramanathan, R., Lopez, Meena, Hegde, Rashmi, Gogtay, Jaideep, and Goregaonkar, Geeta
- Subjects
- *
OBSTRUCTIVE lung diseases , *RESPIRATORY therapy - Abstract
Inhalation therapy is the cornerstone of chronic obstructive pulmonary disease (COPD) management. However, for many COPD patients who are managed at home, nebulization therapy offers an effective alternative treatment and fulfills the gap of catering to the specific population of patients who are unable to use handheld inhaler devices appropriately. The present review highlights key aspects, namely selection of the right beneficiaries for home nebulization, available drugs in nebulized formulations for the treatment of COPD, and the importance of care, cleaning, and maintenance, which are prerequisites for ensuring successful nebulization therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Nebulized lignocaine for topical anaesthesia in no-sedation bronchoscopy (NEBULA): A randomized, double blind, placebo-controlled trial.
- Author
-
Madan, Karan, Biswal, Shiba Kalyan, Tiwari, Pawan, Mittal, Saurabh, Hadda, Vijay, Mohan, Anant, Khilnani, Gopi C., and Guleria, Randeep
- Subjects
- *
BRONCHOSCOPY , *LIDOCAINE , *VISUAL analog scale , *ANESTHESIA , *NEBULAE - Abstract
The role of nebulized lignocaine administration for flexible bronchoscopy is unclear. Methods: In this randomized, double‑blind, placebo‑controlled trial, subjects undergoing diagnostic flexible bronchoscopy were randomized to receive either nebulized lignocaine (2.5 ml of 4% lignocaine) or nebulized (2.5 ml of 0.9%) saline (placebo). All received 10% lignocaine pharyngeal spray (4 sprays) and 5‑ml nasal 2% lignocaine gel. 1% lignocaine solution was used for spray‑as‑you‑go administration in all. Co‑primary outcomes were Operator‑rated overall procedure satisfaction and Operator‑rated cough scores on Visual Analog Scale (VAS). Secondary objectives were cumulative lignocaine dose, proportion of subjects receiving >8.2‑mg/kg lignocaine, and complications between the groups. Results: Two hundred and twenty subjects were randomized and 217 (109 – nebulized lignocaine and 108 – placebo) received the intervention. Baseline characteristics were comparable. Operator‑rated overall procedure satisfaction scores on VAS (7.30 ± 1.54 nebulized lignocaine and 7.50 ± 1.31 placebo group, P = 0.85) and Operator‑rated cough scores on VAS (3 [2–5] nebulized lignocaine and 3 [2–4] placebo group, P = 0.18) were similar. Cumulative lignocaine dose was significantly greater in nebulized lignocaine group (331.46 ± 9.41 mg vs. 232.22 ± 12.77 mg, P < 0.001), and a significantly greater number of subjects in this group received lignocaine dose >8.2 mg/kg. Minor complications occurred in 6 and 9 subjects in nebulized lignocaine and placebo groups, respectively, P = 0.41. Conclusion: Administration of nebulized lignocaine in addition to pharyngeal lignocaine spray, during no‑sedation bronchoscopy, increases the cumulative lignocaine dose without improved procedural comfort. Additional nebulized lignocaine during bronchoscopy is not recommended. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis
- Author
-
Jagadevappa S Patil, V Kusum Devi, Kshama Devi, and S Sarasija
- Subjects
Freeze-dried liposomes ,intra-tracheal instillation ,nebulization ,pulmonary delivery ,rifampicin ,tuberculosis ,Diseases of the respiratory system ,RC705-779 - Abstract
Background: Lung administration of antibiotics by nebulization is promising for improved treatment efficiency for pulmonary infections, as it increases drug concentration at sites of infection while minimizing systemic side effects. For poorly soluble molecules like rifampicin, lipid particulate system may improve lung delivery. Materials and Methods: We investigated rifampicin-loaded freeze-dried liposomes. Various formulations were prepared with different drug lipid ratios and one formulation was optimized. Optimized colloidal liposome formulation was freeze-dried and subsequently subjected for various evaluation and characterization parameters such as in-vitro dissolution, in-vitro antitubercular activity, aerodynamic characters, surface morphology, and thermal behavior. The optimized formulation of rifampicin-loaded freeze-dried liposome and free rifampicin was subjected for the in-vivo drug disposition study in Wister rat model by intra-tracheal instillation in comparison with an oral route of administration. Results: The results of pharmacokinetic study for both free drug and the formulation suggested that liposomes released the drug in a controlled manner for a longer period of time. The enhanced efficiency of drug incorporated into liposomes suggested that the delivery of encapsulated drugs to macrophages was more rapid than that of free drug. Conclusion: Therefore, the pharmacokinetic and drug disposition studies provided a sound basis for predicting the successful treatment for tuberculosis.
- Published
- 2015
- Full Text
- View/download PDF
6. The emerging role of nebulization for maintenance treatment of chronic obstructive pulmonary disease at home
- Author
-
Geeta Goregaonkar, R Ramanathan, Rashmi Hegde, Deepak Talwar, Jaideep Gogtay, and Meena Lopez
- Subjects
Pulmonary and Respiratory Medicine ,lcsh:RC705-779 ,medicine.medical_specialty ,COPD ,home nebulization ,Inhalation ,business.industry ,Copd patients ,nebulization ,Inhaler ,Pulmonary disease ,nebulizer ,Review Article ,lcsh:Diseases of the respiratory system ,medicine.disease ,Alternative treatment ,chronic obstructive pulmonary disease ,Nebulizer ,inhalation therapy ,maintenance nebulization ,medicine ,Available drugs ,Intensive care medicine ,business - Abstract
Inhalation therapy is the cornerstone of chronic obstructive pulmonary disease (COPD) management. However, for many COPD patients who are managed at home, nebulization therapy offers an effective alternative treatment and fulfills the gap of catering to the specific population of patients who are unable to use handheld inhaler devices appropriately. The present review highlights key aspects, namely selection of the right beneficiaries for home nebulization, available drugs in nebulized formulations for the treatment of COPD, and the importance of care, cleaning, and maintenance, which are prerequisites for ensuring successful nebulization therapy.
- Published
- 2021
7. A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis.
- Author
-
Patil, Jagadevappa S., Devi, V. Kusum, Devi, Kshama, and Sarasija, S.
- Subjects
- *
TUBERCULOSIS treatment , *ORAL medication , *RIFAMPIN , *LIPOSOMES , *DRUG delivery systems , *LUNG physiology , *PHARMACOKINETICS , *MACROPHAGES , *THERAPEUTICS - Abstract
Background: Lung administration of antibiotics by nebulization is promising for improved treatment efficiency for pulmonary infections, as it increases drug concentration at sites of infection while minimizing systemic side effects. For poorly soluble molecules like rifampicin, lipid particulate system may improve lung delivery. Materials and Methods: We investigated rifampicin-loaded freeze-dried liposomes. Various formulations were prepared with different drug lipid ratios and one formulation was optimized. Optimized colloidal liposome formulation was freeze-dried and subsequently subjected for various evaluation and characterization parameters such as in-vitro dissolution, in-vitro antitubercular activity, aerodynamic characters, surface morphology, and thermal behavior. The optimized formulation of rifampicin-loaded freeze-dried liposome and free rifampicin was subjected for the in-vivo drug disposition study in Wister rat model by intra-tracheal instillation in comparison with an oral route of administration. Results: The results of pharmacokinetic study for both free drug and the formulation suggested that liposomes released the drug in a controlled manner for a longer period of time. The enhanced efficiency of drug incorporated into liposomes suggested that the delivery of encapsulated drugs to macrophages was more rapid than that of free drug. Conclusion: Therefore, the pharmacokinetic and drug disposition studies provided a sound basis for predicting the successful treatment for tuberculosis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Nebulized lignocaine for topical anaesthesia in no-sedation bronchoscopy (NEBULA): A randomized, double blind, placebo-controlled trial
- Author
-
Anant Mohan, Pawan Tiwari, Vijay Hadda, Shiba Kalyan Biswal, Karan Madan, Randeep Guleria, Saurabh Mittal, and Gopi C Khilnani
- Subjects
Pulmonary and Respiratory Medicine ,Visual analogue scale ,Sedation ,medicine.medical_treatment ,Placebo-controlled study ,Placebo ,Double blind ,03 medical and health sciences ,0302 clinical medicine ,Bronchoscopy ,cough ,medicine ,030212 general & internal medicine ,Saline ,lcsh:RC705-779 ,Topical anaesthesia ,medicine.diagnostic_test ,nebulization ,business.industry ,lcsh:Diseases of the respiratory system ,030228 respiratory system ,Anesthesia ,Original Article ,lignocaine ,medicine.symptom ,business - Abstract
Background: The role of nebulized lignocaine administration for flexible bronchoscopy is unclear. Methods: In this randomized, double-blind, placebo-controlled trial, subjects undergoing diagnostic flexible bronchoscopy were randomized to receive either nebulized lignocaine (2.5 ml of 4% lignocaine) or nebulized (2.5 ml of 0.9%) saline (placebo). All received 10% lignocaine pharyngeal spray (4 sprays) and 5-ml nasal 2% lignocaine gel. 1% lignocaine solution was used for spray-as-you-go administration in all. Co-primary outcomes were Operator-rated overall procedure satisfaction and Operator-rated cough scores on Visual Analog Scale (VAS). Secondary objectives were cumulative lignocaine dose, proportion of subjects receiving >8.2-mg/kg lignocaine, and complications between the groups. Results: Two hundred and twenty subjects were randomized and 217 (109 – nebulized lignocaine and 108 – placebo) received the intervention. Baseline characteristics were comparable. Operator-rated overall procedure satisfaction scores on VAS (7.30 ± 1.54 nebulized lignocaine and 7.50 ± 1.31 placebo group, P = 0.85) and Operator-rated cough scores on VAS (3 [2–5] nebulized lignocaine and 3 [2–4] placebo group, P = 0.18) were similar. Cumulative lignocaine dose was significantly greater in nebulized lignocaine group (331.46 ± 9.41 mg vs. 232.22 ± 12.77 mg, P < 0.001), and a significantly greater number of subjects in this group received lignocaine dose >8.2 mg/kg. Minor complications occurred in 6 and 9 subjects in nebulized lignocaine and placebo groups, respectively, P = 0.41. Conclusion: Administration of nebulized lignocaine in addition to pharyngeal lignocaine spray, during no-sedation bronchoscopy, increases the cumulative lignocaine dose without improved procedural comfort. Additional nebulized lignocaine during bronchoscopy is not recommended.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.